Altria Rises 13% YTD: Should You Buy, Sell or Hold the Stock?

Altria (MO) is up 12.8% YTD and posted 2Q26 adjusted EPS of $1.48 (+2.8% YoY) and 1H adjusted EPS of $2.80 (+4.9%), supported by disciplined pricing despite cigarette volume declines. Smoke-free growth is progressing with on! PLUS expanding to 120,000 stores and resuming shipments of the 12-mg product, while cigarette shipment volume fell 3.2% YoY and inventory-adjusted volume fell ~4.5% in 2Q. Valuation screens as supportive (forward P/E 11.24 vs. industry 15.00), but Zacks EPS estimates for 2026 ($5.67) and 2027 ($5.84) were revised down, and oral tobacco revenues declined 5.3% in 2Q—leaving the stock rated a Zacks Rank #3 (Hold).

Analysis

The key market mechanism is not “growth” but durability of cash flows: MO can keep EPS flat to low-single digits as long as pricing outpaces volume attrition, which makes it more of a high-yield defensive than a secular compounder. That supports valuation on the downside, but it also caps rerating potential because the business mix is still anchored to shrinking categories; the market will likely pay for yield, not for the smoke-free narrative, until on! PLUS proves it can scale without heavy promo intensity.

Relative winners are PM and, to a lesser extent, BTI on a valuation basis. PM’s higher multiple is justified by a cleaner smoke-free mix and broader optionality, while MO’s domestic exposure makes its transition more execution-sensitive and more exposed to U.S. regulatory and elasticity risks. The real loser is TPB: a smaller player in a crowded nicotine pouch market with less pricing power and less room to absorb promotional spending, so any category share fight will pressure margins before it shows up in revenue.

The contrarian view is that the market may be too comfortable treating MO as “cheap.” If oral tobacco keeps leaking share and cigarette declines remain mid-single digits, the current multiple is not obviously a bargain; it is a value trap unless on! PLUS can show sustained retail share gains over the next 1-2 quarters. The key falsifier for the bearish relative view is a clean acceleration in pouch scan data and a stabilization in oral tobacco gross profit, which would support a rerating despite weak legacy volumes.

Key Decisions for Investors

• Maintain MO as a dividend/defensive hold, not an aggressive overweight. The setup favors collecting cash yield while waiting for 1-2 quarters of proof on on! PLUS; if retail-share data or gross profit fails to improve by the next earnings cycle, the thesis weakens materially.
• Express the cleaner smoke-free mix via long PM / short MO for the next 1-3 months. PM should retain a premium if investors keep rewarding mix shift and international smoke-free scale; cover the pair if MO shows a sustained pouch inflection or if PM multiple expansion stalls.
• Use TPB as the highest-conviction relative short in the group on any bounce. Its higher valuation and weaker operating leverage make it most vulnerable to promotional escalation; the trade breaks if category scan data show TPB regaining share or if management signals better margin discipline.
• For event-driven accounts, buy a modest MO put spread into the next earnings/retail-share update rather than outright shorting. The risk/reward is better if the market is over-assigning value to on! PLUS before proof of durable contribution arrives.
• Set a watch item on FDA/regulatory headlines around nicotine pouches and flavors. Any tightening would hit the smoke-free re-rate thesis first; conversely, a benign regulatory backdrop plus sustained pouch gains would be the catalyst to revisit a long MO exposure.